Niche Plays Drive Hong Kong's Fringe Market as mRNA, Robotics Gain Traction

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Hong Kong's overlooked equities are carving divergent paths amid broader market stagnation. Evergreen MedSci (1952.HK) surged 8% intraday after recruiting key architects of Moderna's mRNA-4157 cancer vaccine, positioning its self-owned platform as a rare China-based alternative in the global mRNA race. The move comes as CRRC (1766.HK) gains momentum from its Mexican rail contract, with new energy segment revenues jumping 62.63% sequentially in Q2 2026.

Meanwhile, Joyson Electronics (0699.HK) exemplifies the robotics supply chain spillover effect—its Hong Kong shares spiked 10% when Tesla initiated Optimus production audits in Ningbo, though profit-taking erased most gains by week's end. Asymchem (6821.HK) tells a contrasting story: despite Goldman Sachs' upbeat CDMO sector forecast, the stock plunged 11.85% following regulatory concerns over export controls on biotech know-how.

Traditional sectors show stark contrasts. Energy & Power Global (1142.HK) saw volatile swings after its 10-for-1 share consolidation, while Wanhui Technology (0894.HK) tumbled 19% amid passive component demand slump. Zhonghui Group (0382.HK) reported declining domestic education revenue but 24.25% overseas growth, and Tongtian Winery (0389.HK) posted 47.58% annual revenue growth despite wine industry headwinds.

Source: Global Report The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.